Quick Answer
AVENUE THERAPEUTICS, INC. reported Diluted EPS of $0.22 per share (loss) for fiscal year 2021.
AVENUE THERAPEUTICS, INC. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2021 | -$0.22 | +29.0% |
| 2020 | -$0.31 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2023 | $0.06 | +113.3% | +113.3% |
| September 30, 2022 | -$0.45 | +43.0% | -1400.0% |
| June 30, 2022 | -$0.03 | +50.0% | +78.6% |
| March 31, 2022 | -$0.14 | -133.3% | +82.3% |
| September 30, 2021 | -$0.79 | -1216.7% | -1216.7% |
| June 30, 2021 | -$0.06 | — | +0.0% |
| March 31, 2021 | -$0.06 | — | +0.0% |
| September 30, 2020 | -$0.06 | — | — |
- AVENUE THERAPEUTICS, INC. showed an increase of +29.0% in Diluted EPS compared to the prior fiscal year.
- Over the 2020–2021 period, AVENUE THERAPEUTICS, INC.’s diluted eps has grown by 29.0% (from $0.31 per share (loss) to $0.22 per share (loss)).
- The most recent figure is from AVENUE THERAPEUTICS, INC.’s fiscal year 2021 report (Form 10-K), filed with the SEC on March 25, 2022.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: